Dementia and Alzheimer Disease

The investigational therapy was safe, well-tolerated, and showed promising improvements in cognitive measures among patients with dementia with Lewy bodies.

The cumulative incidence of dementia was higher in people with OSA, particularly for women, across different age groups.

Most recently reported topline data from the RewinD-LB phase 2b trial in patients with dementia with Lewy bodies showed that neflamapimod failed to meet its primary end point and secondary end points.

Here's some of what is coming soon to NeurologyLive® this week.

Krista L. Lanctôt, PhD, professor of psychiatry and pharmacology at the University of Toronto, talked about findings from a recent post hoc analysis presented at CTAD 2024 on nabilone for agitation in Alzheimer disease.

Factors like education level, hypertension, diabetes, and depression did not significantly predict epilepsy risk in patients with dementia.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 6, 2024.

Catch up on any of the neurology news headlines you may have missed over the course of November 2024, compiled all into one place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

The application is based on a large-scale phase 3 study in which blarcamesine demonstrated a significant decline in disease progression compared with placebo over a 48-week period.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 29, 2024.

Applied Therapeutics noted that it is reviewing the FDA's feedback and will request a meeting to discuss requirements for either a resubmission of the NDA or appeal of the agency's decision.

The vice president of scientific engagement at the Alzheimer's Association discussed advancements in blood biomarker tests, their use in specialty care, and the development of clinical guidelines for broader integration.

AL002 did not meet the primary endpoint of slowing Alzheimer's clinical progression, as measured by the Clinical Dementia Rating Sum of Boxes and showed no treatment effects on secondary clinical and functional endpoints.

Over 1 year of treatment, simufilam failed to distinguish itself from placebo on the primary end points of Alzheimer’s Disease Assessment Scale-Cognitive Subscale 12 and Alzheimer’s Disease Cooperative Study-Activities of Daily Living.

Here's some of what is coming soon to NeurologyLive® this week.

Jessica Langbaum, PhD, the senior director of research strategy at Banner Alzheimer’s Institute, discussed the challenges and opportunities in improving diversity in Alzheimer disease clinical trials.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 22, 2024.

The trial, a 20-week study assessing lamotrigine in DLB, will use change in Clinical Dementia Rating-Sum of Boxes as the primary efficacy end point, with several other notable secondary outcomes.

Over a 12-month treatment period, patients on deferiprone demonstrated decreased blood ferritin and hippocampal QSM but caused accelerated cognitive decline and increased regional brain atrophy.

The associate professor of neurology at Georgetown University provided clinical insight on the origins of nilotinib and its medicinal promise in treating patients with Dementia with Lewy bodies, a neurodegenerative disorder.

The change in opinion was after reconsidering the totality of data from the phase 3 Clarity AD trial, a large-scale study of lecanemab featuring more than 1500 patients with early-stage Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 15, 2024.

The software, designed using thousands of brain MRI scans, is used for automated detection and severity grading of ARIA-E and ARIA-H for safety monitoring of new Alzheimer disease therapies.

Neal K. Shah, CEO at CareYaya Health Technologies, shared his perspective on how the new administration could unleash innovation in neurotech, reduce regulatory barriers with Elon Musk’s involvement, and accelerate innovations that could improve neurological care for those with Alzheimer and dementia.

The chief operating officer at Quanterix Corporation talked about pioneering ultra-sensitive blood biomarkers for Alzheimer clinical diagnosis, aiming to enhance detection of brain-derived tau and amyloid status with innovative assays. [WATCH TIME: 4 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of October 2024, compiled all into one place by the NeurologyLive® team.